Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

CRVO

CervoMed Inc.

Pharmaceutical Preparations · SIC 2834CIK 1053691Held by 0 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$4.0M
Net Income FY2025
$(27.0M)
EPS (Basic, as reported)
$-2.98
Net Margin FY2025
-673.1%
ROE FY2025
-148.0%
Total Equity
$18.0M
Shares Out
15M
Business description

CervoMed Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2010–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 0 → 4
Fiscal yearFY2016FY2017⚑FY2018FY2019FY2020FY2021⚑FY2022⚑FY2023⚑FY2024FY2025
Revenue——————07104
Cost of revenue——————————
Gross profit——————————
Research & development(7)(5)(6)(7)(9)(8)(7)(8)(19)(22)
General & administrative(11)(6)(6)(5)(6)(7)(9)(7)(9)(10)
Total operating expenses——————(3)(15)(28)(32)
Operating income(18)(11)(19)(12)(16)(25)(16)(8)(18)(28)
Interest expense000———00——
Interest & investment income——————0021
Other income (expense), net——————(2)621
Pre-tax income(18)(2)(19)(11)(16)(25)(16)———
Income tax expense0(1)00(2)00——0
Net income(18)(1)(18)(12)(14)(24)(16)(2)(16)(27)
EPS — basic($1.76)($0.21)($8.21)($1.76)($0.30)($0.25)($7.65)($0.82)($2.02)($2.98)
EPS — diluted($1.76)——$6706509.00$53831973.00$97626748.00————
Shares outstanding — basic (M)10123———1389
Shares outstanding — diluted (M)10133———————

Showing the latest 10 of 16 fiscal years.

  • ⚑ Weighted-average shares changed ÷4.00 between FY2017 and FY2018 — likely a reverse split. Per-share figures on either side are as reported and not adjusted.
  • ⚑ Weighted-average shares changed ÷3.03 between FY2018 and FY2022 — likely a reverse split. Per-share figures on either side are as reported and not adjusted.
  • ⚑ Weighted-average shares changed ×3.00 between FY2022 and FY2023 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
  • ⚑ Weighted-average shares changed ×2.67 between FY2023 and FY2024 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.